We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ORA:EURONEXT PARISOrange SA Analysis

Data as of 2026-06-25 - not real-time

$124.18

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Ormat Technologies has posted a spectacular 75.8% revenue surge and its stock has rallied more than 16% since the latest earnings release, underscoring strong top‑line momentum. Operating margins above 20% and a solid profit margin of 11% demonstrate operational efficiency, yet the company’s free cash flow remains negative and debt‑to‑equity exceeds 125%, flagging balance‑sheet strain. The current price of $124.18 sits above the 200‑day SMA but below the 20‑day and 50‑day SMAs, while a RSI of 39.5 hints at near‑oversold conditions and the bearish MACD suggests short‑term downside pressure. Support around $123 offers a technical floor, with resistance near $146.4 providing upside potential if the bullish trend persists. Valuation metrics are stretched: a PE of ~60 versus an industry average of ~21 and a DCF fair value of $88.5 place the stock in the overvalued zone, though analyst targets imply a modest 7‑8% upside. The dividend yield of 0.39% and a payout ratio under 25% make the payout sustainable, but the high leverage and 30‑day volatility of over 40% amplify risk. Recent news of accelerated Enhanced Geothermal System deployments and the launch of the Ormega100 unit adds a growth catalyst, aligning with the company’s renewable‑energy focus. Overall, the stock balances strong growth narratives against elevated valuation and financial risk, suggesting a cautious but optimistic stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support at $123
  • Bearish MACD histogram indicating short‑term pressure
  • High 30‑day volatility

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust 75.8% revenue growth and expanding geothermal portfolio
  • Analyst consensus buy with median target $132.5
  • Sustainable dividend and low payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Renewable‑energy tailwinds and EGS deployment acceleration
  • Diversified geographic footprint reducing single‑country exposure
  • Long‑term upside potential despite current overvaluation

Key Metrics & Analysis

Financial Health

Revenue Growth75.80%
Profit Margin10.96%
P/E Ratio60.0
ROE4.91%
ROA2.03%
Debt/Equity125.51
P/B Ratio3.0
Op. Cash Flow$325.7M
Free Cash Flow$-178817120
Industry P/E21.0

Technical Analysis

TrendBullish
RSI39.5
Support$123.00
Resistance$146.39
MA 20$135.63
MA 50$126.48
MA 200$114.42
MACDBearish
VolumeStable
Fear & Greed Index88.16

Valuation

Fair Value$88.51
Target Price$133.75
Upside/Downside7.71%
GradeOvervalued
TypeBlend
Dividend Yield0.39%

Risk Assessment

Beta0.88
Volatility41.61%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.